Amneal Pharmaceuticals Inc. is dedicated to advancing healthcare through a diverse portfolio of approximately 280 generic and specialty pharmaceuticals, with a strong emphasis on innovative drug delivery technologies. The company has developed proprietary platforms that enhance the efficacy, tolerability, and compliance of challenging compounds, particularly in the treatment of conditions such as Parkinson's disease and oncology. Their commitment to the Parkinson's community is exemplified by products like CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules and Naloxone Nasal Spray, which aim to improve patient outcomes and accessibility to essential medications.

The company's manufacturing capabilities are extensive, with state-of-the-art facilities located in the U.S., India, and Ireland. Amneal's operations encompass a wide range of dosage forms, including complex oral solids, injectables, and transdermals, supported by robust internal active pharmaceutical ingredient (API) manufacturing. Recent acquisitions, such as Puniska Healthcare, have further strengthened their injectables infrastructure, enabling them to meet growing market demands and expand into international markets. Amneal's ongoing investment in research and development ensures a continuous pipeline of innovative products, reflecting their commitment to improving health and making "healthy possible."

United States

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

Cancer

Central Nervous System (CNS)

Lung Diseases

Nervous System Diseases

Psychological Diseases

Amneal Pharmaceuticals Inc.

Neutropenia

Releuko®

Biosimilars

Parkinson's disease

IPX203 is a novel, oral formulation of CD/LD extended-release capsules designed for the treatment of Parkinson’s disease. IPX203 contains immediate-release granules and extended-release beads. The IR granules consist of CD and LD, with a disintegrant polymer to allow for rapid dissolution. The ER beads consist of LD, coated with a sustained release polymer to allow for slow release of the drug, a mucoadhesive polymer to keep the granules adhered to the area of absorption longer, and an enteric coating to prevent the granules from disintegrating prematurely in the stomach.

CREXONT® (Carbidopa & Levodopa) (IPX203)

Chemotherapy-induced neutropenia

RELEUKO® (filgrastim-ayow)

Malignant pleural/peritoneal mesothelioma

Small cell lung cancer

PEMRYDI RTU® is indicated, in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberration and for initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

PEMRYDI RTU®

Narcolepsy

Sodium Oxybate Oral Solution carries a boxed warning for central nervous system (CNS) depression and abuse and misuse. Taking Sodium Oxybate with other Central Nervous System (CNS) depressants has been associated with trouble breathing (respiratory depression), low blood pressure (hypotension), changes in alertness (drowsiness), fainting (syncope), and death.
Sodium Oxybate is a form of gamma hydroxybutyrate (GHB). Abuse or misuse of illegal GHB alone or with other CNS depressants (drugs that cause changes in alertness or consciousness) may result in seizures, trouble breathing (respiratory depression), changes in alertness (drowsiness), coma, and death. Patients on Sodium Oxybate should be monitored for confusion, anxiety, and suicidality.

 Xyrem® (sodium oxybate) Generic

Attention deficit hyperactivity disorder

Lisdexamfetamine Dimesylate

Opioid overdose

Naloxone Hydrochloride (Naloxone HCI) Nasal Spray is designed to rapidly reverse the effects of a life-threatening opioid emergency by binding to opioid receptors and reversing or blocking the effects of opioids. It can restore normal breathing within two to three minutes in a person whose breath has slowed, or even stopped, as a result of an overdose from opioids — including heroin, fentanyl and prescription opioid medications. Naloxone HCI Nasal Spray contains the same active ingredient and dose as NARCAN® Naloxone HCI Nasal Spray, 4 mg. It is easy to carry and can be safely used even if opioids are not present.
When using this product some people may experience symptoms when they wake up, such as shaking, sweating, nausea, or feeling angry. This is to be expected.

Amneal Pharmaceuticals Inc.

Company Details